NeuroPace (NASDAQ:NPCE) Downgraded by Wall Street Zen to Sell

NeuroPace (NASDAQ:NPCE) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other analysts also recently issued reports on NPCE. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NeuroPace in a research report on Wednesday, July 29th. Cantor Fitzgerald restated an “overweight” rating on shares of NeuroPace in a research report on Tuesday, September 15th. KeyCorp lowered their target price on shares of NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday. Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Finally, Wells Fargo & Company lowered shares of NeuroPace from an “overweight” rating to an “equal weight” rating and set a $9.00 target price for the company. in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.50.

NeuroPace Stock Performance

NASDAQ NPCE opened at $7.56 on Friday. The company’s 50 day simple moving average is $13.21 and its two-hundred day simple moving average is $14.75. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. NeuroPace has a 1 year low of $5.46 and a 1 year high of $19.60. The stock has a market capitalization of $259.46 million, a PE ratio of -13.50 and a beta of 1.98.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The firm had revenue of $22.83 million during the quarter, compared to analyst estimates of $22.61 million. NeuroPace had a negative net margin of 20.00% and a negative return on equity of 110.26%. Analysts predict that NeuroPace will post -0.67 earnings per share for the current fiscal year.

Institutional Trading of NeuroPace

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in NeuroPace in the second quarter worth $41,000. Algert Global LLC lifted its position in NeuroPace by 2.9% during the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock valued at $2,936,000 after buying an additional 5,218 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of NeuroPace during the 2nd quarter valued at $157,000. Lazard Asset Management LLC boosted its holdings in shares of NeuroPace by 9.8% during the 1st quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock valued at $1,635,000 after buying an additional 11,078 shares in the last quarter. Finally, Diversified Trust Co bought a new stake in shares of NeuroPace during the 3rd quarter valued at $153,000. Institutional investors own 78.83% of the company’s stock.

Key Stories Impacting NeuroPace

These are some of the NPCE stories that stood out recently:

• Negative Sentiment: Q3 revenue was $23.1 million, below the cited $27.1 million analyst estimate. Revenue from the company’s RNS System grew just 1.4% year over year, signaling limited near-term growth. NeuroPace Q3 results and guidance
• Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
• Negative Sentiment: Analyst actions added pressure: JPMorgan cut its rating to neutral and lowered its target from $20 to $9; Wells Fargo and Leerink Partners also downgraded the shares. KeyCorp maintained an overweight rating but cut its target from $18 to $14. Analyst rating changes

About NeuroPace

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.